Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Neuraxpharm Appoints New Country Manager For Spain

Multiple Trade Groups Have All Appointed New Executives

Executive Summary

Neuraxpharm has nabbed its second Almirall ex-employee in recent weeks, appointing Alfredo Barón as its new country manager for Spain. Plus, multiple trade groups expand their ranks and Perrigo promotes Alison Ives to chief scientific officer.

You may also be interested in...



Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios

CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.

Burton Takes Lead At AAM’s Biosimilars Council

Craig Burton is stepping up to become executive director of the US Association for Accessible Medicines’ Biosimilars Council, as Christine Simmon has moved on to become president and CEO of the Food and Drug Law Institute. At the same time, Burton has added oversight of strategic alliances to his existing policy role with the AAM.

Neuraxpharm Expands In Switzerland With New Local Head

Neuraxpharm has appointed Jörg Gärtner to lead its business in Switzerland, as the CNS specialist prepares to roll out its medical cannabis portfolio in the region.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel